Professor Steve Nissen, Cleveland Clinic Foundation, Ohio, USA, reports results of a single ascending dose study of the siRNA, zerlasiran (SLN36), in participants with elevated Lp(a), which demonstrate the safety and efficacy of zerlasiran and support its further development.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
